KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K–MAPK1 inhibition

Human hepatic vascular cavernomas, the most common benign tumor of the liver, were described in the mid-1800s, yet the mechanisms for their formation and effective treatments remain unknown. Here, we demonstrate gain-of-function mutations in KRAS or BRAF genes within liver endothelial cells as a cau...

Descripción completa

Detalles Bibliográficos
Autores principales: Janardhan, Harish Palleti, Meng, Xiuling, Dresser, Karen, Hutchinson, Lloyd, Trivedi, Chinmay M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336315/
https://www.ncbi.nlm.nih.gov/pubmed/32405640
http://dx.doi.org/10.1084/jem.20192205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336315/
https://www.ncbi.nlm.nih.gov/pubmed/32405640
http://dx.doi.org/10.1084/jem.20192205

Ejemplares similares